Aiwu Ruth He, MD, PhD, Discusses 3-Year Survival Data for Durvalumab Plus Chemo in Biliary Tract Cancer, Other Advances

This interview will appear in the June issue of Evidence-Based Oncology.

Related Keywords

Washington ,United States ,American ,Astrazeneca Daiichi Sanyko ,Shubh Goel ,Van Custem ,American Cancer Society ,Astrazeneca Pharmaceuticals ,Astrazeneca ,Medstar Health ,Evidence Based Oncology ,Durable After ,Cholangiocarcinoma Foundation Conference ,Georgetown University ,Lombardi Comprehensive Cancer Center ,Medstar Georgetown University Hospital ,Daiichi Sanyko ,Updated March ,